The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?
The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?
复制标题
全球丁型肝炎病毒（HDV）流行：需要解决哪些差距，以便开展公共卫生应对？
DOI：
10.1186/s13690-021-00693-2
复制
发表时间：
2021-10-19
期刊：
影响因子：
--
通讯作者：
Bulterys M
中科院分区：
文献类型：
--
作者：
Hayashi T;Takeshita Y;Hutin YJ;Harmanci H;Easterbrook P;Hess S;van Holten J;Oru EO;Kaneko S;Yurdaydin C;Bulterys M
B型肝炎病毒（HBV）和丁型肝炎病毒（HDV）的共感染引起最严重的慢性肝炎，并且与肝硬化和肝细胞癌（HCC）的高风险相关。全球卫生部门病毒性肝炎战略呼吁到2030年消除肝炎（死亡率为-65%，发病率为-90%）。我们的目标是总结知识的关键点，并确定需要解决的差距，以建立对HDV的公共卫生响应。我们进行了目前的文献综述流行病学的世界卫生组织地区，基因型分布及其致病性，与HDV感染的相关因素，死亡率由于HDV感染，检测策略和治疗。感染的流行率和基因型分布不均匀，在地中海周围、中东、中亚、北方亚洲和东亚流行率最高。注射毒品者和来自高流行地区的移民受到严重影响。虽然抗体检测测试是可用的，但目前感染的HDV RNA测试没有标准化，也没有广泛使用。包括lofartinib在内的少数治疗选择尚未广泛使用;然而，一些新的和有前途的药物已进入临床试验。HDV感染是慢性肝病的一个鲜为人知的原因。为了采取公共卫生应对措施，我们需要更好地描述HDV流行，标准化检测策略和更好的治疗方案。
Co-infection between hepatitis B virus (HBV) and hepatitis delta virus (HDV) causes the severest chronic hepatitis and is associated with a high risk of cirrhosis and hepatocellular carcinoma (HCC). The Global Health Sector Strategy on Viral Hepatitis called for the elimination of hepatitis (− 65% mortality and − 90% incidence) by 2030. Our aims were to summarize key points of knowledge and to identify the gaps that need to be addressed to mount a public health response to HDV. We performed a current literature review in terms of epidemiology by WHO regions, genotypes distribution and their pathogenicity, factors associated with HDV infection, mortality due to HDV infection, testing strategies and treatment. Prevalence of infection and genotypes are heterogeneous distributed, with highest prevalence in foci around the Mediterranean, in the Middle East, and in Central, Northern Asia and Eastern Asia. Persons who inject drugs (PWID) and migrants from highly endemic areas are highly affected. While antibody detection tests are available, HDV RNA tests of current infection are not standardized nor widely available. The few therapeutic options, including lofartinib, are not widely available; however several new and promising agents have entered clinical trials. HDV infection is an poorly known cause of chronic liver disease. To mount a public health response, we need a better description of the HDV epidemic, standardized testing strategies and better treatment options.
登录
查看更多内容
影响因子：
4.8
作者：
di Filippo Villa D;Cortes-Mancera F;Payares E;Montes N;de la Hoz F;Arbelaez MP;Correa G;Navas MC
通讯作者：
Navas MC
影响因子：
3.7
作者：
Perazzo H;Pacheco AG;Luz PM;Castro R;Hyde C;Fittipaldi J;Rigolon C;Cardoso SW;Grinsztejn B;Veloso VG
通讯作者：
Veloso VG
影响因子：
2.7
作者：
Celik, Inci;Karatayli, Ersin;Bozdayi, A. Mithat
通讯作者：
Bozdayi, A. Mithat
影响因子：
13.5
作者：
Castelnau, Corinne;Le Gal, Frederic;Gault, Elyanne
通讯作者：
Gault, Elyanne
影响因子：
2.8
作者：
Attaran, Mona Seyed;Sharifi, Zohreh;Ataee, Zahrah
通讯作者：
Ataee, Zahrah